Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.

Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M.

Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.

PMID:
24638849
[PubMed - in process]
Free PMC Article
2.

A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.

Dranitsaris G, Beegle N, Kalberer T, Blau S, Cox D, Faria C.

J Oncol Pharm Pract. 2014 Mar 11. [Epub ahead of print]

PMID:
24620009
[PubMed - as supplied by publisher]
3.

Risk prediction models for chemotherapy-induced nausea and vomiting: almost ready for prime time?

Dranitsaris G, Clemons M.

Support Care Cancer. 2014 Apr;22(4):863-4. doi: 10.1007/s00520-014-2134-2. Epub 2014 Jan 29. No abstract available.

PMID:
24474600
[PubMed - indexed for MEDLINE]
4.

Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost.

Dranitsaris G, Ellis AK.

J Eval Clin Pract. 2014 Jun;20(3):225-38. doi: 10.1111/jep.12112. Epub 2014 Jan 21.

PMID:
24444390
[PubMed - in process]
5.

Preference weights for chemotherapy side effects from the perspective of women with breast cancer.

Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, Dent SF, Song X, Segal R, Mazzarello S, Crawley F, Dranitsaris G, Clemons M.

Breast Cancer Res Treat. 2013 Nov;142(1):101-7. doi: 10.1007/s10549-013-2727-3. Epub 2013 Oct 16.

PMID:
24129976
[PubMed - indexed for MEDLINE]
6.

Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada.

Abbott R, Edwards S, Whelan M, Edwards J, Dranitsaris G.

J Oncol Pharm Pract. 2014 Feb;20(1):29-39. doi: 10.1177/1078155213504975. Epub 2013 Oct 8.

PMID:
24103897
[PubMed - in process]
7.

Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic.

Edwards SJ, Abbott R, Edwards J, LeBlanc M, Dranitsaris G, Donnan J, Laing K, Whelan MA, MacKinnon NJ.

J Pharm Pract. 2014 Feb;27(1):46-52. doi: 10.1177/0897190013504954. Epub 2013 Sep 24.

PMID:
24065784
[PubMed - in process]
8.

Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.

Dranitsaris G, Schmitz S, Broom RJ.

J Cancer Res Clin Oncol. 2013 Nov;139(11):1917-26. doi: 10.1007/s00432-013-1510-5. Epub 2013 Sep 14. Review.

PMID:
24037486
[PubMed - indexed for MEDLINE]
9.

Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia.

Chiarotto JA, Dranitsaris G.

Support Care Cancer. 2013 Oct;21(10):2727-31. doi: 10.1007/s00520-013-1851-2. Epub 2013 May 26.

PMID:
23708859
[PubMed - indexed for MEDLINE]
10.

Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre.

Dent S, Fraser J, Graham N, Campbell M, Hopkins S, Dranitsaris G.

Curr Oncol. 2013 Feb;20(1):24-9. doi: 10.3747/co.20.1202.

PMID:
23443761
[PubMed]
Free PMC Article
11.

Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.

Bouganim N, Dranitsaris G, Hopkins S, Vandermeer L, Godbout L, Dent S, Wheatley-Price P, Milano C, Clemons M.

Curr Oncol. 2012 Dec;19(6):e414-21. doi: 10.3747/co.19.1074.

PMID:
23300365
[PubMed]
Free PMC Article
12.

Clinical trial design in biosimilar drug development.

Dranitsaris G, Dorward K, Hatzimichael E, Amir E.

Invest New Drugs. 2013 Apr;31(2):479-87. doi: 10.1007/s10637-012-9899-2. Epub 2012 Nov 17. Review.

PMID:
23161336
[PubMed - indexed for MEDLINE]
13.

Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience.

Zhu X, Bouganim N, Vandermeer L, Dent SF, Dranitsaris G, Clemons MJ.

Curr Oncol. 2012 Aug;19(4):e239-43. doi: 10.3747/co.19.948.

PMID:
22876152
[PubMed]
Free PMC Article
14.

Evaluating the impact of bevacizumab maintenance therapy on overall survival in advanced non-small-cell lung cancer.

Dranitsaris G, Beegle N, Ravelo A, Kalberer T, Yu E, Thomas S.

Clin Lung Cancer. 2013 Mar;14(2):120-7. doi: 10.1016/j.cllc.2012.06.002. Epub 2012 Aug 4.

PMID:
22868222
[PubMed - indexed for MEDLINE]
15.

Are EstringĀ® and VagifemĀ® equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy?

Simmons CE, Kuchuk I, Freedman OC, Colgan T, Dodd A, Kulhanek K, Sheiner J, Dranitsaris G, Dowsett M, Folkerd E, Clemons MJ.

Clin Oncol (R Coll Radiol). 2012 Oct;24(8):e128-9. doi: 10.1016/j.clon.2012.06.009. Epub 2012 Jul 12. No abstract available.

PMID:
22795828
[PubMed - indexed for MEDLINE]
16.

Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer.

Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M.

Am J Clin Oncol. 2013 Oct;36(5):436-42. doi: 10.1097/COC.0b013e3182568f7a.

PMID:
22781385
[PubMed - indexed for MEDLINE]
17.

Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting.

Dranitsaris G, Bouganim N, Milano C, Vandermeer L, Dent S, Wheatley-Price P, Laporte J, Oxborough KA, Clemons M.

J Support Oncol. 2013 Mar;11(1):14-21.

PMID:
22763232
[PubMed - indexed for MEDLINE]
18.

Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in malaysia.

Dranitsaris G, Truter I, Lubbe MS, Sriramanakoppa NN, Mendonca VM, Mahagaonkar SB.

Malays J Med Sci. 2011 Oct;18(4):32-43.

PMID:
22589671
[PubMed]
Free PMC Article
19.

Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.

Dranitsaris G, Hatzimichael E.

Support Care Cancer. 2012 Jul;20(7):1353-60. doi: 10.1007/s00520-012-1461-4. Epub 2012 Apr 27. Review.

PMID:
22539050
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Meta-regression analysis to indirectly compare prophylaxis with dalteparin or enoxaparin in patients at high risk for venous thromboembolic events.

Dranitsaris G, Jelincic V, Choe Y.

Clin Appl Thromb Hemost. 2012 Jun;18(3):233-42. doi: 10.1177/1076029611426869. Epub 2012 Mar 2. Review.

PMID:
22387576
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk